Rituximab Treatment in Myasthaenia Gravis: Report of two paediatric cases

Roshan Koul, Amna Al-Futaisi, Rana Abdelrahim, Renjith Mani, Reem Abdwani, Abdullah Al-Asmi

Abstract


Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.


Keywords: Myasthenia Gravis; Rituximab; Children; Cholinergic Receptors; Case Report; Oman.


Full Text:

PDF


DOI: http://dx.doi.org/10.18295/squmj.2018.18.02.018

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Sultan Qaboos University Medical Journal, College of Medicine and Health Sciences, Sultan Qaboos University, PO Box 35, Postal Code 123, Al-Khod, Muscat, Oman

ISSN (Print edition): 2075-051X ISSN (Internet edition): 2075-0528

Copyright SQUMJ 2018. This journal and its content is licensed under a Creative Commons Attribution No Derivatives 4.0 International license.

Flag Counter